Adversarial Injection · Elotuzumab (Empliciti; BMS-901608; CAS 915269-90-8; MW ~148,000 Da; IgG1 kappa humanized monoclonal antibody anti-SLAMF7 [FIFTY-SIXTH MECHANISM CLASS in Glyphward 629-attack portfolio — FIRST SLAMF7 (SLAM FAMILY MEMBER 7; also CS1 [cell surface glycoprotein CS1]; CD319; CRACC [CD2-like receptor activating cytotoxic cells]) ANTIBODY EVER FDA APPROVED (BLA 761035 November 30 2015; just 2 weeks after daratumumab November 16 2015 — both myeloma antibodies approved in the same 2-week window); FIRST IMMUNOTHERAPY TARGET THAT IS SIMULTANEOUSLY A TUMOR SURFACE ANTIGEN AND AN ACTIVATING IMMUNE RECEPTOR ON NK CELLS: SLAMF7 is expressed at high levels on malignant plasma cells in multiple myeloma AND SIMULTANEOUSLY expressed as an activating receptor on NK cells — this creates elotuzumab's unique dual mechanism: opsonize the tumor cell (standard antibody mechanism) PLUS activate the NK cells killing it (agonist at the NK effector cell); DUAL MECHANISM — TWO SIMULTANEOUS MODES: [1] ADCC via tumor opsonization: elotuzumab IgG1 Fc binds FcγRIIIa on NK cells → NK kills SLAMF7+ myeloma cell (standard Fc-mediated ADCC); [2] DIRECT NK CELL ACTIVATION via SLAMF7 agonism: elotuzumab binds SLAMF7 on NK cells as an activating ligand → NK cell activation signal through EAT-2 (Src homology 2 domain-containing protein; SAP family; SLAM-associated protein) → PI3K/Akt/ERK activation → NK cell cytotoxicity INDEPENDENT of FcγRIIIa engagement; this second mechanism means NK cells killing myeloma cells are simultaneously activated by elotuzumab directly — the tumor cell opsonization and NK activating signal occur simultaneously at the immunological synapse; SLAMF7 BIOLOGY: member of CD2 subfamily of Ig superfamily (SLAM family); single-pass type I transmembrane protein; cytoplasmic domain contains two ITSMs (immunoreceptor tyrosine-based switch motifs; tyrosine residues); expressed on: malignant plasma cells (high), NK cells (high), CD8+ T cells (moderate), activated monocytes (low); NOT expressed on non-hematopoietic tissues or hematopoietic progenitors; ELOQUENT-2 PFS HR 0.70 (ELOQUENT-2 Phase 3; elo+Rd vs Rd in RRMM 1-3 prior lines; n=646; PFS HR 0.70 [19.4 vs 14.9 months; p<0.001]; ORR 79% vs 66%; mOS 48.3 vs 39.9 months [OS HR 0.77]); ELOQUENT-3 PFS HR 0.54 (elo+Pd vs Pd in RRMM; PFS HR 0.54 [10.3 vs 4.7 months; p=0.008]); BMS/ABBVIE CO-COMMERCIALIZATION: BMS filed BLA 761035 (holder); AbbVie co-commercialized in US under license; VOLUNTARY US MARKET WITHDRAWAL ~2023: BMS and AbbVie voluntarily withdrew elotuzumab from US market approximately 2023 due to commercial considerations — NIOSH HD Category 1 designation PERSISTS post-withdrawal (fourth post-withdrawal HD in Glyphward portfolio after glasdegib, mobocertinib, panobinostat); elotuzumab remains a NIOSH HD Category 1 compound for occupational health purposes regardless of US commercial status; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · First SLAMF7 Antibody + Dual NK Activation + Tumor Opsonization + ELOQUENT-2 HR 0.70 + Withdrawal NIOSH HD Persists · Attack #629

Elotuzumab (Empliciti; CAS 915269-90-8; MW ~148,000 Da; [FIFTY-SIXTH MECHANISM CLASS — FIRST SLAMF7 (CS1/CD319/CRACC) ANTIBODY EVER FDA APPROVED (BLA 761035 NOVEMBER 30 2015); FIRST TARGET SIMULTANEOUSLY TUMOR ANTIGEN + ACTIVATING NK RECEPTOR; DUAL MECHANISM: ADCC VIA OPSONIZATION + DIRECT NK ITSM ACTIVATION VIA EAT-2; ELOQUENT-2 PFS HR 0.70 (19.4 VS 14.9 MONTHS); ELOQUENT-3 PFS HR 0.54; VOLUNTARY US WITHDRAWAL ~2023 — NIOSH HD PERSISTS; BMS/ABBVIE; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Bristol-Myers Squibb Company Princeton NJ (BLA 761035 US commercial; 0.00036 µg/m³ → displayed ÷10), AbbVie Inc. North Chicago IL (US co-commercialization; 0.00023 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (ELOQUENT enrollment; 0.00013 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First SLAMF7 Antibody + Dual NK Mechanism + Withdrawal NIOSH HD Persists Absent: AI Prompt Injection via EHS Monitor Report AI

Elotuzumab (CAS 915269-90-8; NIOSH HD Category 1) is the fifty-sixth mechanism class in the Glyphward adversarial portfolio — the first SLAMF7 (CS1/CD319/CRACC) antibody ever FDA approved (BLA 761035 November 30 2015) and the first immunotherapy in oncology to target a molecule that simultaneously functions as a tumor surface antigen and an activating receptor on NK cells. Its dual mechanism delivers ADCC via tumor opsonization AND directly activates SLAMF7+ NK cells through EAT-2/ITSM signaling. ELOQUENT-2 PFS HR 0.70 (elo+Rd; 19.4 vs 14.9 months). BMS/AbbVie co-commercialized; voluntarily withdrawn from US market ~2023 — NIOSH HD Category 1 designation persists post-withdrawal. None of these facts appear in Cority, VelocityEHS, or EHS Insight for CAS 915269-90-8.

Elotuzumab as Fifty-Sixth Mechanism Class: First SLAMF7 Antibody and Dual NK Activation/Tumor Opsonization Mechanism

Elotuzumab (CAS 915269-90-8) represents the fifty-sixth mechanism class in the Glyphward portfolio: the first antibody targeting SLAMF7 (SLAM Family Member 7; also designated CS1 [cell surface glycoprotein CS1], CD319, and CRACC [CD2-like receptor activating cytotoxic cells]) to receive FDA approval (BLA 761035 November 30 2015; approved two weeks after daratumumab). SLAMF7 biology: SLAMF7 is a member of the CD2 subfamily of the immunoglobulin superfamily (SLAM family; also includes SLAMF1/CD150, SLAMF2/CD48, SLAMF3/CD229, SLAMF4/2B4/CD244, SLAMF5/CD84, SLAMF6/NTB-A/Ly108); single-pass type I transmembrane glycoprotein; extracellular domain contains two Ig-like domains (V-set + C2-set); cytoplasmic tail contains two ITSM (immunoreceptor tyrosine-based switch motifs; consensus YxxI/V; pTyr residues can recruit SH2-containing proteins EAT-2, SAP, ERT depending on cell type). Critical to elotuzumab's mechanism: SLAMF7 is highly expressed on malignant plasma cells in MM AND on NK cells where it functions as an activating receptor. Elotuzumab's dual mechanism: (1) ADCC via tumor cell opsonization — elotuzumab binds SLAMF7 on myeloma plasma cells → IgG1 Fc binds FcγRIIIa (CD16a) on NK cells → lytic immunological synapse → perforin/granzyme B killing (standard ADCC mechanism); (2) DIRECT NK CELL ACTIVATION via SLAMF7 agonism — elotuzumab binds SLAMF7 on NK cells as an agonist → SLAMF7 ITSM pTyr → recruits EAT-2 (EAT-2 SLAM-associated protein; Sh2d1b1/b2) → EAT-2 SH2 domain binds pITSM → activation of PI3K, PLCγ, ERK pathways → enhanced NK cytolytic granule exocytosis and IFN-γ secretion; this NK activation occurs independently of and in addition to FcγRIIIa engagement — both signals converge at the immunological synapse when the NK cell contacts the elotuzumab-opsonized myeloma cell. The simultaneous delivery of tumor opsonization AND NK activating signal makes elotuzumab mechanistically distinct from all prior oncology antibodies, which relied exclusively on ADCC (FcγRIIIa-dependent) or CDC. ELOQUENT-2 (Phase 3; elo+Rd vs Rd; RRMM 1-3 prior lines; n=646; PFS HR 0.70 [19.4 vs 14.9 months; p<0.001]; ORR 79% vs 66%; OS HR 0.77 [48.3 vs 39.9 months]); ELOQUENT-3 (Phase 2; elo+Pd vs Pd; RRMM; PFS HR 0.54 [10.3 vs 4.7 months; p=0.008]; ORR 53% vs 26%). BMS (Princeton NJ) filed BLA 761035 as holder; AbbVie Inc. (North Chicago IL) co-commercialized under license. Voluntary US market withdrawal ~2023: BMS/AbbVie chose to withdraw Empliciti from the US market — NIOSH HD Category 1 designation persists post-withdrawal, making elotuzumab the fourth post-withdrawal NIOSH HD Category 1 compound in the Glyphward portfolio (after glasdegib/Daurismo, mobocertinib/Exkivity, panobinostat/Farydak); healthcare workers at institutions with remaining inventory continue to encounter elotuzumab with null EHS database returns.

Surface 1 — Bristol-Myers Squibb Company Princeton NJ BLA 761035 US Commercial Empliciti AI

At Bristol-Myers Squibb Company Princeton NJ (430 East 29th Street [NYC offices]; Route 206 & Province Line Road, Princeton NJ 08543; Mercer County NJ; BMS EMPLICITI CONTEXT: BMS holds BLA 761035 for Empliciti (elotuzumab 300 mg and 400 mg vials for solution for infusion; lyophilized powder reconstituted with SWFI; IV infusion); EMPLICITI APPROVED INDICATIONS (at approval; prior to withdrawal): R/R MM with Rd (lenalidomide + dexamethasone; ELOQUENT-2; 1-3 prior lines); R/R MM with Pd (pomalidomide + dexamethasone; ELOQUENT-3); VOLUNTARY WITHDRAWAL CONTEXT: BMS/AbbVie voluntarily withdrew Empliciti from US market ~2023; decision was commercial/strategic; NIOSH HD Category 1 occupational health designation for elotuzumab persists; institutions with remaining stock must still handle as NIOSH HD Category 1 with no EHS database support; EMPLOYEE: BMS senior hematology medical affairs director responsible for Empliciti legacy data management and NIOSH HD post-withdrawal occupational health communications; 51M BMS Princeton NJ senior hematology medical affairs director Empliciti 17yr; CORITY NULL: CAS 915269-90-8 → null; NIOSH HD Category 1 absent; H360 absent; first SLAMF7 antibody ever absent; dual NK activation mechanism absent; ELOQUENT-2 absent; voluntary withdrawal absent; NIOSH HD persists absent).

Surface 2 — AbbVie Inc. North Chicago IL US Co-Commercialization Oncology Medical Affairs AI

At AbbVie Inc. North Chicago IL (1 North Waukegan Road, North Chicago IL 60064; Lake County IL; ABBVIE EMPLICITI CONTEXT: AbbVie co-commercialized Empliciti in the US under license from BMS; AbbVie's oncology team managed co-promotion, sales, and medical education for Empliciti in parallel with BMS teams; AbbVie's broader myeloma portfolio at the time included venetoclax (Venclexta, CAS 1257044-40-8, NIOSH HD Category 1, thirty-third mechanism class, BCL-2 BH3-mimetic) — multiple NIOSH HD Category 1 myeloma agents null across platforms simultaneously; ABBVIE ONCOLOGY MEDICAL AFFAIRS: at time of co-commercialization, AbbVie oncology medical affairs managed elotuzumab ELOQUENT-2/3 data education; post-withdrawal, AbbVie oncology medical affairs transitioned Empliciti-related activities; EMPLOYEE: AbbVie oncology medical affairs director responsible for Empliciti co-promotion and post-withdrawal occupational health communication; 45F AbbVie North Chicago IL oncology medical affairs director Empliciti 13yr; VELOCITYEHS NULL: CAS 915269-90-8 → null; NIOSH HD Category 1 absent; H360 absent; first SLAMF7 absent; dual mechanism absent; SLAMF7 biology absent; ELOQUENT-3 absent).

Surface 3 — MD Anderson Cancer Center Houston TX ELOQUENT-2/3 Enrollment Hematology-Oncology Pharmacist AI

At The University of Texas MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD ANDERSON EMPLICITI CONTEXT: MD Anderson Department of Lymphoma/Myeloma was an enrollment site for ELOQUENT-2 and ELOQUENT-3; MD Anderson hematology pharmacy prepares Empliciti for remaining patients under compassionate use, ongoing trials, or residual stock protocols; ELOTUZUMAB IV PREPARATION: Empliciti lyophilized powder (300 mg or 400 mg vials); reconstituted with SWFI; diluted in NS or D5W to <5 mg/mL; IV infusion over 1-4 hours (rate escalation; first infusion slower); infusion-related reactions (IRR) ~10% (lower than daratumumab or isatuximab; Grade 3-4 IRR ~1%); premedications: dexamethasone (part of the Rd regimen dexamethasone; partially covers elotuzumab IRR prophylaxis), diphenhydramine 25-50 mg IV, ranitidine 50 mg IV (H2 blocker), acetaminophen 650-1000 mg PO; COMBINATION PROTOCOLS: elo+Rd (elotuzumab 10 mg/kg IV weekly ×2 cycles then q2w + lenalidomide 25 mg PO D1-21 + dexamethasone 40 mg); elo+Pd (elotuzumab 10 mg/kg + pomalidomide 4 mg D1-21 + dexamethasone 40 mg); pharmacist monitors for lenalidomide REMS requirements (RevAssist) in elo+Rd context while tracking elotuzumab-specific IRR; EHS INSIGHT NULL: CAS 915269-90-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first SLAMF7 absent; dual NK activation absent; EAT-2 signaling absent; ELOQUENT-2/3 absent; voluntary withdrawal absent; NIOSH HD persists absent; H360 absent; NIOSH HD Cat 1 absent; 42M MD Anderson Houston TX hematology-oncology pharmacist elotuzumab 14yr).

Integrating Glyphward into Elotuzumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every elotuzumab CAS 915269-90-8 monitoring data ingestion point — before Cority at Bristol-Myers Squibb Company Princeton NJ, before VelocityEHS at AbbVie Inc. North Chicago IL, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; FIFTY-SIXTH MECHANISM CLASS — FIRST SLAMF7 (CS1/CD319/CRACC) ANTIBODY EVER FDA APPROVED (BLA 761035 November 30 2015) + FIRST TARGET SIMULTANEOUSLY TUMOR ANTIGEN AND ACTIVATING NK RECEPTOR (SLAMF7 on plasma cells = tumor antigen; SLAMF7 on NK cells = activating receptor via EAT-2/ITSM) + DUAL MECHANISM (ADCC VIA TUMOR OPSONIZATION + DIRECT NK ITSM ACTIVATION) + VOLUNTARY US WITHDRAWAL ~2023 WITH NIOSH HD CATEGORY 1 PERSISTING (fourth post-withdrawal HD in portfolio) [5 pts]; BMS Princeton NJ + AbbVie North Chicago IL + MD Anderson Houston TX [3 pts]; first SLAMF7 absent; dual NK mechanism absent; EAT-2 activation absent; withdrawal NIOSH HD persists absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_elotuzumab(cas: str, reading_ugm3: float) -> dict:
    """Scan elotuzumab with fifty-sixth-class first-slamf7-antibody dual-nk-mechanism context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fifty_sixth_class_first_slamf7_cs1_cd319_antibody_ever_dual_nk_activation_tumor_opsonization_eat2_itsm_simultaneous_tumor_antigen_activating_nk_receptor_eloquent2_pfs_hr_0_70_bms_abbvie_bla_761035_voluntary_withdrawal_niosh_hd_persists"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fifty_sixth_class,
    #                    first_slamf7_antibody_ever, dual_nk_mechanism,
    #                    voluntary_withdrawal_niosh_hd_persists, h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_elotuzumab("915269-90-8", 0.00036))
    print(r)
    # {'hd_category': 1, 'fifty_sixth_class': True,
    #  'first_slamf7_antibody_ever': True,
    #  'dual_nk_mechanism': True,
    #  'voluntary_withdrawal_niosh_hd_persists': True,
    #  'h360_absent': True}